作者
Todd C. Hollon,Balaji Pandian,Arjun Adapa,Esteban Urias,Akshay Save,Siri Sahib S. Khalsa,Daniel G. Eichberg,Randy S. D’Amico,Zia Farooq,Spencer Lewis,Petros Petridis,Tamara Marie,Ashish H. Shah,Hugh Garton,Cormac O. Maher,Jason Heth,Erin L. McKean,Stephen E. Sullivan,Shawn L. Hervey-Jumper,Parag G. Patil,B. Gregory Thompson,Oren Sagher,Guy M. McKhann,Ricardo J. Komotar,Michael E. Ivan,Matija Snuderl,Marc L. Otten,Timothy D. Johnson,Michael B. Sisti,Jeffrey N. Bruce,Karin M. Muraszko,J. K. Trautman,Christian W. Freudiger,Peter Canoll,Honglak Lee,Sandra Camelo‐Piragua,Daniel A. Orringer
摘要
Intraoperative diagnosis is essential for providing safe and effective care during cancer surgery1. The existing workflow for intraoperative diagnosis based on hematoxylin and eosin staining of processed tissue is time, resource and labor intensive2,3. Moreover, interpretation of intraoperative histologic images is dependent on a contracting, unevenly distributed, pathology workforce4. In the present study, we report a parallel workflow that combines stimulated Raman histology (SRH)5–7, a label-free optical imaging method and deep convolutional neural networks (CNNs) to predict diagnosis at the bedside in near real-time in an automated fashion. Specifically, our CNNs, trained on over 2.5 million SRH images, predict brain tumor diagnosis in the operating room in under 150 s, an order of magnitude faster than conventional techniques (for example, 20–30 min)2. In a multicenter, prospective clinical trial (n = 278), we demonstrated that CNN-based diagnosis of SRH images was noninferior to pathologist-based interpretation of conventional histologic images (overall accuracy, 94.6% versus 93.9%). Our CNNs learned a hierarchy of recognizable histologic feature representations to classify the major histopathologic classes of brain tumors. In addition, we implemented a semantic segmentation method to identify tumor-infiltrated diagnostic regions within SRH images. These results demonstrate how intraoperative cancer diagnosis can be streamlined, creating a complementary pathway for tissue diagnosis that is independent of a traditional pathology laboratory. A prospective, multicenter, case–control clinical trial evaluates the potential of artificial intelligence for providing accurate bedside diagnosis of patients with brain tumors.